Asthma Symptoms Pneumonia RSV Respiratory Syncytial Virus (RSV) COVID-19 COVID-19 Tests Chronic Obstructive Pulmonary Disease Influenza Infections Flu Chronic Obstructive Pulmonary Disease (COPD) Bronchiolitis Atemwegserkrankungen Lung Cancer Acute Respiratory Infections Air Pollution Emphysema Human Metapneumovirus Cancer Impact of Pollution Bronchitis RSV (Respiratory Syncytial Virus) COPD Chronic Conditions Common Cold Flu and COVID-19 Lung Disease Lung Diseases Chronic Diseases Covid-19 Air Quality Outdoor Exertion Measles Fine-Particle Pollution Pulmonary Fibrosis Hospital Visits Lung Infections Bordetella Pertussis Breathing Problems Air Quality Index Effects of Air Pollution Cardiovascular Diseases Pre-existing Conditions Rise Children Mycoplasma Pneumonias Pneumonia-like Infections Interstitial Lung Diseases Lockdowns Heart Diseases Interstitial Lung Disease Mask Mandates Complications Hospitalizations Heart Attacks Pollution-related Illnesses Toxic Exposure Child Health Coughing Illnesses Nasal Health Pollution-related Health Problems Upper Respiratory Infections Lung Emphysema Pulmonary Conditions Smoke Exposure RS Virus Atemwegsinfekte Environmental Health
The biotech firm beats Wall Street estimates, expands cost-reduction targets, and delays its COVID-flu combo vaccine approval to 2026.